Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426
Authors
Rini, B. I.Plimack, E. R.
Stus, V.
Gafanov, R.
Waddell, Thomas
Nosov, D.
Pouliot, F.
Alekseev, B.
Soulieres, D.
Melichar, B.
Vynnychenko, I. O.
Azevedo, S. J.
Borchiellini, D.
McDermott, R. S.
Bedke, J.
Tamada, S.
Wu, S.
Burgents, J.
Molife, L. R.
Powles, T.
Affiliation
Vanderbilt-Ingram Cancer Center, Nashville, TNIssue Date
2023
Metadata
Show full item recordCitation
Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. Journal of Clinical Oncology. 2023 Jun;41(17). PubMed PMID: WOS:001043181100025.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.17_suppl.LBA4501Additional Links
https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA4501Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.17_suppl.LBA4501